🧪 It highlights the need for improved purification and quantitation techniques as mRNA usage expands beyond vaccines.
🔬 Key solutions include a dsRNA-specific affinity resin and innovative variable pathlength technology for accurate measurement.
💡 Upcoming insights stem from a webinar featuring experts from Rice University and Repligen.
Introduction:
This article discusses the emerging strategies for the removal of double-stranded RNA (dsRNA) contaminants and the accurate quantitation of messenger RNA (mRNA) in the context of evolving mRNA modalities used in therapeutics. As the landscape of mRNA therapeutics expands beyond vaccines to include diverse applications, the purification and quantitation methods must adapt to ensure product quality and consistency.
- The rise of mRNA therapeutics generates increased expectations for purification and quality control, necessitating improved methods to match the advanced manufacturing challenges.
- Double-stranded RNA (dsRNA) byproducts present significant complications during the purification of RNA-based vaccines and therapeutics.
- Current traditional methods, such as UV quantitation, can result in inaccuracies due to necessary sample handling and dilutions.
- Novel purification techniques, including a dsRNA-specific affinity chromatography resin, can effectively remove dsRNA contaminants while also mitigating immune responses in cellular assays.
- The introduction of variable pathlength technology promises enhanced accuracy and reproducibility for mRNA quantification, thus improving overall manufacturing processes.
Conclusion:
The advancements in purification and quantitation methods for mRNA therapeutics highlighted in this article indicate a significant evolution in the field. These developments, particularly in addressing dsRNA contamination, are crucial for the reliability and safety of mRNA therapeutics as they expand beyond traditional applications. Ongoing research and adaptation of these techniques will be essential for meeting the stringent demands of modern biopharmaceutical manufacturing.
